Efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma: a systematic review and network meta-analysis.

Front Immunol · 2025 · PMC12183282 · PMID 40552283

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For patients over 50 years old, CamGP (HR = 0.55, 95% CI: 0.36–0.83) was associated with improved PFS, while TorGP showed a trend toward benefit (HR = 0.71, 95% CI: 0.43–1.20) that did not reach statistical significance.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Regarding ORR ( Figure 4 ), both TisGP (OR = 1.47, 95% CI: 1.07–2.03) and TorGP (OR = 1.4, 95% CI: 1.04–1.86) were more likely to achieve a higher response rate compared to standard chemotherapy, whereas CamGP (OR = 1.24, 95% CI: 0.92–1.68) did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.